Heat shock protein 90 (Hsp90) is a molecular chaperone with essential functions in maintaining transformation, and there is increasing interest in developing Hsp90 inhibitors as cancer therapeutics. In this study, the authors describe the development and optimization of a novel assay for the identification of Hsp90 inhibitors using fluorescence polarization. The assay is based on the competition of fluorescently (BODIPY) labeled geldanamycin (GM) for binding to purified recombinant Hsp90α (GM is a natural product that binds to the ATP/ADP pocket in the amino terminal of Hsp90). The authors show that GM-BODIPY binds Hsp90α with high affinity. Even at low Hsp90α concentrations (30 nM), the measured polarization value is close to the maximum assay range of 160 mP, making measurements very sensitive. Its performance, as judged by signal-tonoise ratios (> 10) and Z and Z′ values (> 0.5), suggests that this is a robust and reliable assay. GM, PU24FCl, ADP, and ATP, all known to bind to the Hsp90 pocket, compete with GM-BODIPY for binding to Hsp90α with EC 50 s in agreement with reported values. These data demonstrate that the Hsp90-FP-based assay can be used for high-throughput screening in aiding the identification of novel
H EAT SHOCK PROTEIN 90 (Hsp90) is a molecular chaperone whose association is required for stability and function of multiple mutated, chimeric, and overexpressed signaling proteins that promote cancer cell growth and/or survival. Hsp90 client proteins include Bcr-Abl, Raf-1, mutated p53, Akt, and transmembrane tyrosine kinases (i.e., Her2, EGFR, and Her3). Hsp90 inhibitors, such as geldanamycin (GM) and radicicol, by interacting with the N-terminal ATP/ADP binding pocket, cause the destabilization and proteasomal degradation of Hsp90 client proteins (see reviews by Neckers 1 and Maloney and Workman 2 for detailed information on Hsp90). A less toxic derivative of GM, 17AAG, has shown promising antitumor activity in preclinical model systems 3, 4 and is currently in phase I cancer clinical trials. However, its low solubility and lack of oral availability lessen the enthusiasm for wide clinical use. To fully explore the potential for Hsp90-targeted thera-pies, novel agents that bind to the N-terminus of the chaperone and have more drug-like properties are desirable.
A possible method of searching for new classes of compounds active against the chaperone would be to screen large libraries of compounds for Hsp90 binding. Several methods have been devised to probe the binding of ligands to Hsp90. These include displacement of Hsp90 from immobilized GM, [5] [6] [7] isothermal calorimetry, 8 circular dichroism, 9 measurements of ATPase activity, [10] [11] [12] [13] and, recently, a filter binding assay using [ 3 H]17AAG. 14 Unfortunately, most of these assays are not suitable for high-throughput screening (HTS), they necessitate high amounts of protein, or they depend on radioactive reagents. Here, we present the development, optimization, and validation of an Hsp90 fluorescence polarization assay. The assay is homogenous and quick and may be used for high-throughput drug screening.
MATERIALS AND METHODS
GM-BODIPY was synthesized as previously reported 15 and was dissolved in DMSO to form 10-µM solutions. Hsp90α was purchased from Stressgen Bioreagents (cat. no. SPP-776; Victoria, Canada). The assay buffer (HFB) contained 20 mM HEPES (K) pH 7.3, 50 mM KCl, 5 mM MgCl 2 , 20 mM Na 2 MoO 4 , 0.01% NP40. Before each use, 0.1 mg/mL bovine gamma globulin (BGG; Panvera Corporation, Madison, WI) and 2 mM DTT (Fisher Biotech, Fair Lawn, NJ) were freshly added. GM, dipyridamole, and quinacrine hydrochloride were purchased from Sigma-Aldrich (Milwaukee, WI). The synthesis and characterization of the purine-skeleton Hsp90 inhibitors has been presented elsewhere. 7
Fluorescence polarization measurements
Fluorescence polarization measurements were performed on an Analyst AD instrument (Molecular Devices, Sunnyvale, CA). Measurements were taken in black 96-well microplates (Corning #3650) in which both the excitation and the emission occurred from the top of the wells. In the Analyst AD, a xenon arc lamp provides excitation light that passes through an excitation filter and then a polarizer filter. A beam-splitter filter directs the polarized excitation light into the well, and emitted fluorescence transmits back through the same beam-splitter filter, through a polarizer filter, then through the emission filter for detection. In this study, read time was 0.1 s per well. The excitation polarizer filter was fixed in the parallel position, whereas the emission polarizer filter was changed for measuring parallel and perpendicular emission fluorescence intensity. All polarization values were expressed in millipolarization units ( For BODIPY-labeled compounds, measurements were made with excitation at 485 nm (25-nm bandwidth) and emission at 530 nm (25-nm bandwidth) using a 505-nm beam splitter. Specific binding was defined as the contribution to signal of bound ligand and was calculated as b × mP b = mP -f × mP f , where b and f are the fractions of bound and free tracer, mP is the recorded polarization value for a particular Hsp90 concentration, and mP f if the polarization value for free tracer. The assay window was defined as mP -mP f .
Fluorescence intensity measurements were obtained using a SpectraMax GeminiXS (Molecular Devices, Sunnyvale, CA). The excitation and emission wavelengths were 485 nm and 530 nm, respectively.
Assay optimization for GM-BODIPY/Hsp90
The equilibrium binding experiments of fluorescent GM to Hsp90 were performed under the following conditions: each individual well in a 96-well assay plate contained 5 nM fluorescent GM and increasing concentrations (from 0 to 125 nM) of Hsp90 protein in assay buffer containing the indicated DTT and BGG concentrations in a final volume of 100 µL. The plate was mixed on a slow moving shaker for the indicated times at 4°C. The polarization in mP was measured at room temperature with an excitation wavelength at 485 nm and an emission wavelength at 530 nm. For assay performance indicator determination, a plate containing various amounts of GM-BODIPY with or without 30 nM Hsp90α and 0.5 µM 17AAG was measured as indicated. The signal-tonoise ratio was calculated by using the equation S:
The Z′ factor was calculated by the equation Z′ = 1 -(3SD b + 3SD f )/(µ b -µ f ), and the Z factor was calculated by the equation 16, 17 SD b , SD f , and SD d are standard deviations, and µ b , µ f , and µ d are means for bound, free, and displaced tracer controls (recorded polarization values), respectively. For assay stability testing, a plate containing a binding experiment was measured at different times over several days. The assay equilibration time and its stability were determined by monitoring it at several time intervals, as indicated. Between each reading, the plate was covered with a lid to prevent solution evaporation. To determine the effect of DMSO on the assay, binding experiments were performed under conditions similar to those described above except that the amount of DMSO was varied from 0% to 16% (v/v). All values were normalized to control (values obtained in wells containing the corresponding DMSO volume, tracer, and protein but no competitor) and calculated as percentage control. All experimental data were analyzed using Microsoft ® Excel (Microsoft Corporation, Redmond, WA) and Prism 4.0 (Graphpad Software Inc., San Diego, CA).
Competition assays
For the competition studies, fluorescence polarization assays were performed under the following conditions: each 96-well plate contained 5 nM fluorescent GM, 30 nM Hsp90α protein, and tested inhibitor (initial stock in DMSO) in a final volume of 100 µL. For each assay, background wells (buffer only), tracer controls (free, fluorescent GM only), and bound GM controls (fluorescent GM in the presence of Hsp90) were included on each assay plate. The fraction of tracer bound to Hsp90 was correlated to the mP value and plotted against log 10 values of competitor concentrations. The inhibitor concentrations at which 50% of bound GM was displaced was obtained by fitting the data.
High-throughput assay and data calculations
To evaluate the quality or suitability of the Hsp90 fluorescence polarization assay for HTS, the signal-to-noise ratio and the Z′ factor were determined for the 96-well assay format. 16, 17 Data from twenty 96-well plates that were used in screening our purineskeleton Hsp90 inhibitor library were used to determine the suitability of the assay for HTS. Each plate contained 2 background wells (buffer only), 4 free tracer control wells (5 nM GM-BODIPY), and 4 bound tracer control wells (5 nM GM-BODIPY with 30 nM Hsp90α), and the remaining was divided among tested Hsp90 inhibitors. The mP value for each well was obtained and analyzed. The signal-to-noise ratio and the Z′ factor were calculated as mentioned above.
RESULTS AND DISCUSSION

Development of Hsp90 fluorescence polarization assay
The principle of fluorescence polarization is based on the observation that when a relatively small, fast-tumbling fluorescentlabeled compound is excited with plane-polarized light, the emitted light is random with respect to the plane of polarization, resulting in a lower mP value. 18 When the compound is bound to a bigger molecule (in this case Hsp90), the complex tumbles much slower and the emitted light is polarized, resulting in a higher mP value. Thus, the change of mP reflects the interaction between the fluorescent-labeled compound (in this case GM-BODIPY) and the protein (Hsp90 chaperone). The mP value is proportional to the fractions of bound ligand, and the assay is very powerful in measuring real-time protein-inhibitor interactions in solution.
To develop a fluorescence polarization assay, the binding affinity of the probe to the protein should be high and the binding range (maximum mP at saturation -minimal mP at no protein) should be large. As shown in Figure 1 , at lower Hsp90 concentrations, a low mP value was obtained in the binding of 5 nM GM-BODIPY to Hsp90α; as the concentration of Hsp90 increased, a greater fraction of fluorescent GM was bound to the chaperone, and polarization progressively increased to reach saturation (Fig. 1B) to result in an assay window of~160 mP (Fig. 1A) . Data from the experiments were imported into Prism 4.0 to determine the dissociation constant (K d ; Fig. 2) . The tracer had a K d of 6.6 ± 1.3 nM for Hsp90α. This is reflective of a much higher affinity for Hsp90 than previously reported for unlabeled GM (200 nM to 1 µM). [5] [6] [7] [8] [9] [10] [11] [12] [13] The increased affinity could be a result of BODIPY contribution to binding. BODIPY dyes are relatively nonpolar, and the chromophore is electrically neutral. These properties were found to sometimes enhance the affinity of their ligand conjugates for receptors. It is not to say that BODIPY interacts nonspecifically with Hsp90-methotrexate-BODIPY (Molecular Probes #M-23272, a dihydrofolate reductase ligand) does not induce an increase in polarization in the presence of Hsp90 (not shown). We cannot exclude the fact that this phenomenon can also be reflective of differential GM-BODIPY and GM affinities for Hsp90 forms and conformations. Analysis of the binding by Scatchard and Hill plots suggested the presence of one binding site on reaching equilibrium (Fig. 2) .
The stability of the Hsp90 fluorescent polarization assay using the fluorescent GM ligand is critical for HTS. We tested the stabil-ity by incubating the binding assays at 4°C over a 2-day period. The assay plate was read several times during this period, and the data were collected and analyzed. The results suggested that the assay is stable, as evidenced by the binding curves ( Fig. 1) . As DTT is oxidized over time in the presence of air, it is unlikely that longer storage periods will result in assays with comparable performance.
Competitive binding inhibition assays using GM-BODIPY
To validate the assay for potential high-throughput drug screening and also for investigation of protein-ligand interaction, we have developed a competition fluorescence polarization assay format in which a test set of Hsp90 inhibitors competes with the fluorescent GM for binding to the chaperone. To elucidate the minimum amount of GM-BODIPY that resulted in a robust assay, a plate containing various amounts of GM-BODIPY with or without 30 nM Hsp90α and 0.5 µM GM was measured as indicated (Fig. 3A) . The assay performance parameters signal-to-noise ratio, Z, and Z′ were determined (Fig. 3B) . 16, 17 The Z factor is reflective of both the assay range and the data variation. A Z factor between 0.5 and 1 defines an excellent assay. The Z′ factor is a parameter for the quality of the assay itself without test compounds. Assays with small Z′ factors (negative or close to zero) are not suitable and need to be optimized, whereas assays with Z′ factors close to 1 (the maximum) are of high quality. The test assay resulted in excellent signal-to-noise (~10) ratios and Z′ and Z values (> 0.5) at tracer concentrations above 3.5 nM (Fig.  3B) . The assay window remained greater than 100 mP up to 50 nM GM-BODIPY and greater than 50 mP at 150 nM tracer. To avoid the use of high amounts of tracer but also to eliminate possible inconsistencies in concentration measurements, a GM-BODIPY concentration of 5 nM appeared optimal for use in competitive assays. At this concentration, the fluorescence intensity from the tracer was strong enough to overcome the effect of weakly fluorescent compounds present in our purine-skeleton library of Hsp90 inhibitors or the background fluorescence from the assay buffer (Figs. 3C, D) . Recently, an analysis of possible interference in fluorescence polarization HTS from highly fluorescent compounds was presented by the Schering-Plough group. 19 The authors have identified dipyridamole and quinacrine hydrochloride as extreme fluorescent cases present in the LOPAC™ library of compounds. They suggested that interference from such highly fluorescent compounds might be prevented by increasing the concentration of fluorescent ligand or by using a red-shifted fluorescent label in the assay. Our data imply that concentrations of GM-BODIPY in the 50-to 150-nM range result in strong enough fluorescent signals to overcome interference from highly fluorescent compounds while rendering an assay with acceptable window and performance characteristics (Z and Z′ > 0.5 and signal-to-noise ratio~10; Figs. 3B-D).
Development of a Fluorescence Polarization Assay
The concentration chosen for the Hsp90α protein was 30 nM. At 30 nM Hsp90α, the obtained assay window of~150 mP is close to the maximal assay window (Fig. 1) , making the assay more sensitive.
GM, PU24FCl, ATP, and ADP were studied as competitors due to the fact that the binding affinities of these compounds to Hsp90 have been determined by independent methods. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] EC 50 values for these compounds were determined to be as follows: 76.9 ± 3.5 nM for GM, 140.3 ± 3.9 nM for PU24FCl, 20.0 ± 8.2 µM for ADP, and 100.8 ± 15.0 µM for ATP ( Fig. 4) . Values for GM and the nucleosides correlate with reported affinities (100 nM for GM, 15 µM for ADP, and 150 µM for ATP) determined using an assay that measures competitive binding of radiolabeled 17AAG to the N-terminal domain of Hsp90α. 14 We have previously determined an EC 50 of 450 nM for PU24FCl using a competitive displacement of Hsp90β, another cytosolic Hsp90 family member, from solidphase immobilized GM. 7
Influence of DMSO on competitive binding
DMSO is a common solvent used in dissolving many compounds used for testing. Thus, the Hsp90 fluorescence polarization assay should tolerate the presence of low volumes of DMSO. When we performed the binding and competition assays, we included a maximum 0.25% DMSO in each well (v/v). We have further tested the effect of up to 16% DMSO on the competition experiments. GM was chosen as the test Hsp90 inhibitor. As presented in Figure 5A , the assay window is decreased in the presence of DMSO (158.9 ± 8.8 mP in the absence of DMSO, 145.4 ± 1.6 mP in the presence of 2% DMSO, 130.6 ± 8.1 mP in the presence of 4% DMSO, 111.6 ± 2.3 mP in the presence of 8% DMSO, and 102.3 ± 2.6 mP in the presence of 16% DMSO; Fig. 5A ). However, the obtained EC 50 values remained similar (Fig. 5B) . At 16% DMSO, the assay was somewhat noisier. Thus, the fluorescence polarization assay is reasonably stable in the presence of DMSO at least up to 8%.
High-throughput format development
The fluorescence polarization assay by itself is suitable for HTS because of the minimal steps involved. To determine the precision and robustness of the Hsp90 assay, we tested the well-to-well and plate-to-plate variations of free tracer controls (5 nM GM-BODIPY) and bound tracer controls (recorded polarization values for 5 nM GM-BODIPY with 30 nM Hsp90α) in twenty 96-well plates of experiments conducted on different days (Fig. 6A ). The average for free GM-BODIPY controls was 148.2 mP, with a standard deviation of 9.1 and a standard error of 2.0 (n = 80). The average for bound tracer controls was 311.5 mP, with a standard deviation of 8.6 and a standard error of 1.9 (n = 80). The signal-to-noise ratios determined in each plate were on average higher than 10, which is higher than the minimal acceptable signal-to-noise ratio in the fluorescence polarization assay as recommended by the Analyst vendor (about 8), whereas the Z′ factor was determined to vary between 0.5 and 0.9 (Fig. 6B ). Among the 20 plates, the average value for the signal-to-noise ratio was determined to be 21.5 with a standard deviation of 14.7 and a standard error of 3.3, whereas the average value for the Z′ factor was 0.74 with a standard deviation of 0.13 and a standard error of 0.03. It is likely that robotic handling will reduce variability from plate-to-plate and day-to-day experiments.
Development of a Fluorescence Polarization Assay
In summary, we have established a fluorescence polarization assay for Hsp90 using a fluorescent GM ligand. The assay is fast and robust with good reproducibility, and it performed well in the presence of DMSO; thus, it can be adapted to high-throughput assay format. 
